AVIR
Atea Pharmaceuticals, Inc.Company Information
- Company Name
- Atea Pharmaceuticals, Inc.
- CIK
- CIK0001593899
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- AVIR: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- AVIR
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-05-18
- Last sale
- 2024-12-10
- Shares purchased (TTM)
- 12,200
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 58,585,875
- Shares outstanding
- 80,050,518
- Ownership
- 73.19%
Earnings Market Reaction
- Filing date
- 2026-08-12
- Price on filing date
- —
- 1-month reaction
- 15.22%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 77 | 79 | 96 | 77 | 88 | 119 | 65 | 98 | 243 | 161 | 144 | 138 | ||||||
| Available For Sale Securities Debt Securities Current | 143 | 177 | 206 | 252 | 292 | 306 | 390 | 384 | 259 | 381 | 434 | 457 | ||||||
| Prepaid Expense And Other Assets Current | 9 | 7 | 9 | 7 | 6 | 8 | 8 | 4 | 4 | 7 | 12 | 8 | ||||||
| Assets Current | 229 | 263 | 311 | 336 | 386 | 434 | 462 | 487 | 506 | 549 | 590 | 603 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Other Assets Noncurrent | 3 | 3 | 3 | 5 | 4 | 4 | 0 | 2 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | ||||||
| Assets | 232 | 267 | 315 | 343 | 392 | 440 | 465 | 491 | 510 | 553 | 595 | 608 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 10 | 9 | 13 | 4 | 9 | 7 | 4 | 6 | 5 | 21 | 4 | 0 | ||||||
| Accrued Liabilities And Other Liabilities | 18 | 23 | 26 | 16 | 10 | 14 | 13 | 19 | 20 | 19 | 27 | 18 | ||||||
| Operating Lease Liability Current | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Liabilities Current | 28 | 33 | 40 | 20 | 20 | 22 | 19 | 25 | 27 | 41 | 32 | 19 | ||||||
| Operating Lease Liability Noncurrent | - | - | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | ||||||
| Accrued Income Taxes Noncurrent | - | - | 0 | 7 | 7 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | ||||||
| Liabilities | - | - | 40 | 27 | 27 | 29 | 26 | 32 | 34 | 49 | 40 | 26 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 805 | 802 | 798 | 793 | 800 | 809 | 803 | 788 | 776 | 763 | 751 | 739 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 0 | 0 | 0 | 0 | 0 | 1 | -0 | -0 | 0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -601 | -568 | -523 | -478 | -436 | -398 | -364 | -331 | -300 | -259 | -196 | -157 | ||||||
| Stockholders Equity | 204 | 234 | 275 | 316 | 364 | 411 | 439 | 459 | 476 | 504 | 555 | 582 | ||||||
| Liabilities And Stockholders Equity | 232 | 267 | 315 | 343 | 392 | 440 | 465 | 491 | 510 | 553 | 595 | 608 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | ||||||
| Common Stock Shares Issued | 80 | 80 | 78 | 78 | 81 | 86 | 84 | 84 | 84 | 84 | 83 | 83 | ||||||
| Shares Outstanding | 80 | 80 | 78 | 78 | 81 | 86 | 84 | 84 | 84 | 84 | 83 | 83 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAtea Pharmaceuticals, Inc. (AVIR) — SEC Financial Statements & Analysis
Atea Pharmaceuticals, Inc. (AVIR) is a pharmaceutical preparations company, incorporated in MA. Atea Pharmaceuticals, Inc. trades on Nasdaq as: AVIR. Atea Pharmaceuticals, Inc. (AVIR)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12. Based on that filing, Atea Pharmaceuticals, Inc. carries a market cap of $372.23M, a P/E ratio of -2.25x, a P/B ratio of 1.82x, an enterprise value of $295.69M, and an EV/EBITDA multiple of -1.61x. On profitability, it posts a Return on Equity (ROE) of -58.14%, a Return on Assets (ROA) of -52.99%, and a Return on Invested Capital (ROIC) of -90.83%. Per share, it reports EPS of $-2.06, diluted EPS of $-2.06, free cash flow per share of $-1.90, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of 21.42% year-over-year, and EPS growth of 27.03% year-over-year. On the balance sheet, it maintains a current ratio of 8.13x, a quick ratio of 7.80x, working capital of $200.54M, a debt-to-equity ratio of 0.14x, a debt ratio of 0.12, free cash flow of $-152.07M (TTM), and net debt of $-76.55M. Figures sourced from SEC EDGAR.
- Market Cap
- $372.23M
- P/E TTM
- -2.25x
- EPS TTM
- $-2.06
- P/B TTM
- 1.82x
- ROE TTM
- -58.14%
- ROA TTM
- -52.99%
- Debt To Equity
- 0.14x
- Free Cash Flow TTM
- $-152.07M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Atea Pharmaceuticals, Inc. in?
Atea Pharmaceuticals, Inc. (AVIR) operates in the Pharmaceutical Preparations industry.
What exchange does AVIR trade on?
Atea Pharmaceuticals, Inc. (AVIR) trades on the Nasdaq.
Where is Atea Pharmaceuticals, Inc. incorporated?
Atea Pharmaceuticals, Inc. is incorporated in MA.
When was Atea Pharmaceuticals, Inc. (AVIR)'s most recent SEC filing?
Atea Pharmaceuticals, Inc. (AVIR)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12.
What is AVIR's market cap?
Atea Pharmaceuticals, Inc. (AVIR) has a market capitalization of $372.23M as of 2026-06-30.
What is AVIR's EPS (earnings per share)?
Atea Pharmaceuticals, Inc. (AVIR)'s trailing twelve month EPS is $-2.06 as of 2026-06-30.
What is AVIR's ROE (return on equity)?
Atea Pharmaceuticals, Inc. (AVIR)'s trailing twelve month Return on Equity (ROE) is -58.14% as of 2026-06-30.
What is AVIR's ROA (return on assets)?
Atea Pharmaceuticals, Inc. (AVIR)'s trailing twelve month Return on Assets (ROA) is -52.99% as of 2026-06-30.
What is AVIR's ROIC (return on invested capital)?
Atea Pharmaceuticals, Inc. (AVIR)'s trailing twelve month Return on Invested Capital (ROIC) is -90.83% as of 2026-06-30.
What is AVIR's EV/EBITDA?
Atea Pharmaceuticals, Inc. (AVIR)'s trailing twelve month EV/EBITDA is -1.61x as of 2026-06-30.